ClinicalTrials.gg
CompletedNCT03375788Updated Nov 20, 2025Results posted

Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk

A Phase 2 interventional study of Tesamorelin and Identical Placebo in Non-Alcoholic Fatty Liver Disease, Obesity and Obesity, Abdominal, sponsored by Massachusetts General Hospital. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-11-20.

Sponsored by Massachusetts General Hospital · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Non-alcoholic Fatty Liver Disease by Massachusetts General Hospital — 2 open to participants now, 3 under way, 1 of them phase 3. Non-alcoholic Fatty Liver Disease · Massachusetts General Hospital.

Enrollment
5th of 15
51 · median 40
Started
2019
with 2 others
Phase 2
3 of 16
none open now
Registered
9th of 16
by date

Among the 16 studies in Non-alcoholic Fatty Liver Disease by Massachusetts General Hospital, this one is the 5th largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2019, is one of 3 in phase 2, and was the 9th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

2 of the 16 studies in Non-alcoholic Fatty Liver Disease by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Non-alcoholic Fatty Liver Disease by Massachusetts General Hospital, or all of them as a file.
02

Study summary

Nonalcoholic fatty liver disease (NAFLD) is common in individuals with obesity and is a significant threat to public health, because it can lead to impaired liver function and liver failure. Growth hormone is a hormone produced in the pituitary gland that helps regulate metabolism and growth. Individuals with obesity, on average, secrete less growth hormone than individuals without obesity. There are data to suggest that growth hormone may help to reduce the amount of fat in the liver, and may also reduce inflammation in the liver, both of which would be helpful to individuals with NAFLD. The purpose of this study is to investigate whether treatment with a drug called tesamorelin, which is a growth hormone releasing hormone analogue, will decrease liver fat and improve liver inflammation and scarring in obese individuals with NAFLD.

03

Conditions studied

  • Non-Alcoholic Fatty Liver Disease
  • Obesity
  • Obesity, Abdominal
  • Liver Fat
  • Fatty Liver

Keywords

  • tesamorelin
  • obesity
  • fatty liver
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women 18-65yo
  2. (BMI) ≥ 30kg/m2, or, for participants with known steatohepatitis, BMI ≥ 25kg/m2
  3. Hepatic steatosis as demonstrated by either a) Grade 1+ steatosis on a liver performed within 12 months of the baseline visit, without >10% reduction in body weight or addition of medications to treat fatty liver, or b) liver fat fraction ≥5% on hydrogen-magnetic resonance spectroscopy (1H-MRS)
  4. antibody and surface antigen negative. Subjects without known history of Hepatitis C or Hepatitis C treatment who have a positive Hepatitis C antibody but a negative hepatitis C viral load will also be eligible.
  5. For females ≥50yo, negative mammogram within 1 year of baseline
  6. If use of vitamin E ≥400 international units daily, stable dose for ≥6 mos
  7. Up to date with colon cancer screening recommended by the participant's primary care physician, using whatever methodology the primary physician recommends. This will be ascertained by self-report. (If a participant does not have a primary care physician, we will discuss that colon cancer screening is recommended, typically starting at age 50y, and refer the participant to primary care through Partners if s/he desires.)

Exclusion criteria

Exclusion Criteria:

  1. Heavy alcohol use defined as consumption of > 20 grams daily for women or > 30 grans daily for men for at least 3 consecutive months over the past 5 years assessed using the Lifetime Drinking History Questionnaire
  2. Known diagnosis of diabetes, use of any anti-diabetic medications (including thiazolidinediones or metformin), fasting glucose >126mg/dL, or (HbA1c) ≥6.5%. Participants with stable use of metformin ≥6 months will be permitted if it is being used for pre-diabetes or another non-diabetes indication (e.g., PCOS).
  3. Use of any specific pharmacological treatments for NAFLD/nonalcoholic steatohepatitis except vitamin E
  4. Known cirrhosis, score ≥7, stage 4 fibrosis on , or clinical evidence of cirrhosis or portal hypertension on imaging or exam. If a subject is not known to be cirrhotic at screen but is found to be cirrhotic based on the results of liver biopsy at baseline, this subject will be referred to a hepatologist for clinical care and will be excluded from further participation in the study.
  5. Chronic systemic use in the ≤6 months prior to the baseline visit
  6. Chronic use of Actigall, methotrexate, amiodarone, or tamoxifen
  7. Known diagnosis of alpha-1 antitrypsin deficiency, Wilson's disease, hemochromatosis, or hepatitis
  8. Use of growth hormone or growth hormone releasing hormone within the past 6 months
  9. Change in lipid lowering or anti-hypertensive regimen within 2 months of screening
  10. \< 10.0 g/dL or Creatinine >1.5mg/dL
  11. Active
  12. For men, history of prostate cancer or evidence of prostate malignancy by prostate specific antigen (PSA) > 5 ng/mL
  13. Severe chronic illness judged by the investigator to present a to participation
  14. History of hypopituitarism, head irradiation or any other condition known to affect the GH axis
  15. Use of physiologic testosterone (men) or estrogen or progesterone (women) unless stable use for a year or more prior to study entry
  16. Routine magnetic resonance imaging (MRI) exclusion criteria such as the presence of a pacemaker or cerebral aneurysm clip
  17. Weight loss surgery within 1 year before baseline. Weight loss surgery more than 1 year prior to baseline visit is permissible as long as no active weight loss (\<10% decrease in weight over past 6 months)
  18. For women, positive urine pregnancy test (hCG), trying to achieve pregnancy, or breastfeeding
  19. For women able to become pregnant, unwillingness to use an acceptable form of during the study.
  20. Known to tesamorelin or mannitol
  21. Contraindication to receiving beta-blocker or nitroglycerin (which are part of the coronary angiography)
  22. Significant radiation exposure, including any history of radiation therapy, or any of the following in the 12 months prior to randomization: a) more than 2 percutaneous coronary interventions; b) more than 2 myocardial perfusion studies; 3) more than 2 computed tomography angiograms
  23. Active consideration for a procedure or treatment that involves significant radiation exposure as defined above in the 12 months following randomization
  24. Not willing or able to adhere to dose schedules and required procedures per protocol
  25. Judged by the investigator to be inappropriate for the study for other reasons not detailed above.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    Tesamorelin

    tesamorelin (brand name Egrifta) 2mg daily given subcutaneously

    Drug: Tesamorelin

  • Placebo comparator
    Placebo

    identical placebo given subcutaneously daily

    Drug: Identical Placebo

Interventions

  • Tesamorelin F4 formulation 1.4mg daily

    Also known as: Egrifta, TH9507, Growth Hormone Releasing Hormone Analog

  • DrugIdentical Placebo

    Placebo injection daily

06

What researchers measure

Primary outcomes

  1. Liver Fat Content

    Liver Fat Content as measured by hydrogen-magnetic resonance spectroscopy. All available data used; data not available for 1 participant in tesamorelin group and 3 participants in placebo group.

    Time frame: change from baseline to 12 months

Secondary outcomes

  1. NAFLD Activity Score

    Nonalcoholic Fatty Liver Disease Activity Score (NAS, scored between 0-8, with higher indicating more severe disease) from liver biopsy. All available data used; data not available for 3 participants in placebo group and 1 participant in tesamorelin group.

    Time frame: change from baseline to 12 months

  2. Low Density Lipoprotein (LDL) Cholesterol

    All available data utilized. Data not available for 2 participants in tesamorelin group and 3 participants in placebo group.

    Time frame: change from baseline to 12 months

  3. C-reactive Protein

    All available data utilized. Data not available for 2 participants in placebo group.

    Time frame: change from baseline to 12 months

  4. Fibrosis Score

    fibrosis score from liver biopsy; all available data used - data not available for 1 participant in tesamorelin group and 3 participants in placebo group. Fibrosis stage scored from 0-4, where 0 indicates no fibrosis and 4 indicates most severe fibrosis, which is cirrhosis.

    Time frame: change from baseline to 12 months

07

Results

Posted Nov 20, 2025
Limitations and caveats
Interpretation of changes in biopsy data are limited by relatively small sample size as well as the requirement for steatosis but not steatohepatitis at baseline. In other words, not all participants had steatohepatitis or fibrosis at baseline.

Participant flow

12-month Double-blind Phase
Participant flow — 12-month Double-blind Phase
MilestoneTesamorelinPlacebo
Started2625
Completed1919
Not completed76
6 Month Open Label Phase
Participant flow — 6 Month Open Label Phase
MilestoneTesamorelinPlacebo
Started1713
Completed1612
Not completed11

Outcome measures

PrimaryLiver Fat Content

Liver Fat Content as measured by hydrogen-magnetic resonance spectroscopy. All available data used; data not available for 1 participant in tesamorelin group and 3 participants in placebo group.

Time frame:
change from baseline to 12 months
Reported as:
Median · percent change in hepatic fat fraction
Liver Fat Content
percent change in hepatic fat fractionTesamorelinPlacebo
Liver Fat Content-5.3 (-13.0 to -1.4)3.6 (-6.2 to 7.9)
SecondaryNAFLD Activity Score

Nonalcoholic Fatty Liver Disease Activity Score (NAS, scored between 0-8, with higher indicating more severe disease) from liver biopsy. All available data used; data not available for 3 participants in placebo group and 1 participant in tesamorelin group.

Time frame:
change from baseline to 12 months
Reported as:
Median · units on a scale
NAFLD Activity Score
units on a scaleTesamorelinPlacebo
NAFLD Activity Score0 (-2 to 0)0 (-1 to 1)
SecondaryLow Density Lipoprotein (LDL) Cholesterol

All available data utilized. Data not available for 2 participants in tesamorelin group and 3 participants in placebo group.

Time frame:
change from baseline to 12 months
Reported as:
Mean · milligrams per deciliter
Low Density Lipoprotein (LDL) Cholesterol
milligrams per deciliterTesamorelinPlacebo
Low Density Lipoprotein (LDL) Cholesterol-5.7 ± 27-0.7 ± 16
SecondaryC-reactive Protein

All available data utilized. Data not available for 2 participants in placebo group.

Time frame:
change from baseline to 12 months
Reported as:
Mean · milligrams per liter (mg/L)
C-reactive Protein
milligrams per liter (mg/L)TesamorelinPlacebo
C-reactive Protein-0.9 ± 4.20.0 ± 4.1
SecondaryFibrosis Score

fibrosis score from liver biopsy; all available data used - data not available for 1 participant in tesamorelin group and 3 participants in placebo group. Fibrosis stage scored from 0-4, where 0 indicates no fibrosis and 4 indicates most severe fibrosis, which is cirrhosis.

Time frame:
change from baseline to 12 months
Reported as:
Median · units on a scale
Fibrosis Score
units on a scaleTesamorelinPlacebo
Fibrosis Score0 (0 to 1)0 (0 to 0.5)

Adverse events

Collected over Adverse events for the double-blind phase occurred during months 0-12 of the study (12-month double-blind phase). Adverse events for the open-label phase occurred during months 12-18 of the study (6-month open label phase that occurred at the end of the 12- month double-blind phase).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-blind Phase: Tesamorelin0/26 (0%)2/26 (7.7%)22/26 (84.6%)
Double-blind Phase: Placebo0/25 (0%)3/25 (12%)15/25 (60%)
Open Label Phase0/30 (0%)0/30 (0%)16/30 (53.3%)
Most frequent serious events
Most frequent serious events
EventDouble-blind Phase: TesamorelinDouble-blind Phase: PlaceboOpen Label Phase
rotator cuff surgerySurgical and medical procedures0/261/25—
appendicitisGastrointestinal disorders0/261/25—
major depressive disorderPsychiatric disorders0/261/25—
elective knee replacementSurgical and medical procedures1/260/25—
liver hematoma following biopsyInjury, poisoning and procedural complications1/260/25—
Most frequent other events
Showing 10 of 37
Most frequent other events
EventDouble-blind Phase: TesamorelinDouble-blind Phase: PlaceboOpen Label Phase
Injection site stingingSkin and subcutaneous tissue disorders8/261/259/30
ArthralgiaMusculoskeletal and connective tissue disorders6/261/252/30
EdemaSkin and subcutaneous tissue disorders6/261/251/30
Injection site complaints, otherSkin and subcutaneous tissue disorders5/262/256/30
Injection site erythemaSkin and subcutaneous tissue disorders5/260/253/30
Injection site bruisingSkin and subcutaneous tissue disorders4/261/250/30
HeadacheNervous system disorders1/263/250/30
Joint painMusculoskeletal and connective tissue disorders3/261/250/30
GastrointeritisGastrointestinal disorders2/260/250/30
Injection site itchingSkin and subcutaneous tissue disorders2/260/250/30

Baseline characteristics

Age, Continuous
Age, Continuous(years)TesamorelinPlaceboTotal
Mean47 ± 1047 ± 1147 ± 11
Sex: Female, Male
Sex: Female, Male(Participants)TesamorelinPlaceboTotal
Female121123
Male141428
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)TesamorelinPlaceboTotal
White231538
Black213
Other077
Hispanic ethnicity123
Region of Enrollment
Region of Enrollment(participants)TesamorelinPlaceboTotal
United States262551
08

Study locations

1 site
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Final Research Data, with all patient identifiers removed, will be available to other researchers through request to the PI. Because information contained in the final research data will include multiple demographic and biological variables that could potentially be used in concert to identify participants, it will be shared only under a Data Sharing Agreement that includes (1) a commitment to using the data only for research purposes and not to identify any individual participant and (2) a commitment to destroying or returning the data after analyses are completed.

Supporting information: Study protocol

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in Jul 2024, 65 months.

Results were first posted in Nov 2025, 1 year 4 months after primary completion.

Of 53 non-industry phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 56. This study's 65 months is above that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2017
First posted
Dec 18, 2017
StartActual
Jan 17, 2019
Primary completionActual
Jul 10, 2024
CompletionActual
Jan 10, 2025
Results first posted
Nov 20, 2025
Last update
Nov 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03375788
Responsible party
Takara Stanley (Associate Professor of Pediatrics, Massachusetts General Hospital) — Principal investigator
First posted
Dec 18, 2017
Start date
Jan 17, 2019
Primary completion
Jul 10, 2024
Completion
Jan 10, 2025
Results posted
Nov 20, 2025
Last update
Nov 20, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tesamorelin

Start the discussion